Abstract: Compositions and methods that may be useful for the treatment of a viral infection as well as for treating infection induced cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) are described herein. For example, pharmaceutical compositions containing Compound I as disclosed herein may be used to treat infection by a coronavirus, such as SARS-CoV-2 (“COVID-19”).

Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

Abstract: The present invention relates to new sulfonamide pyrrolopyridine compounds and compositions useful in the treatment of JAK-mediated conditions having the structures of Formula (I), wherein the R groups are as defined in the detailed description. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided. Exemplary indications treated by inhibition of JAK kinase activity include, but are not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, and Celiac disease.

Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

Abstract: A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.

Abstract: Delivery of Janus Kinase 3 (JAK3) inhibitor locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis. This invention facilitates the performance of the stent in inhibiting restonosis.

Abstract: Delivery of a Janus Kinase 3 (JAK3) inhibitor locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis.

Abstract: A method of treating or preventing atherosclerosis comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.

Abstract: Monoclonal antibodies, and a cell line characterized by its production of such monoclonal antibodies, demonstrating specific reactivity to an antigenic determinant possessed by a plurality of types of adenoviruses, a method of isolating such cell lines, and the use of such antibodies for diagnostic and therapeutic purposes as well as for identifying chemical compounds with similar properties, are disclosed.